Catherine L Carmichael
Overview
Explore the profile of Catherine L Carmichael including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zerella J, Homan C, Arts P, Lin X, Spinelli S, Venugopal P, et al.
Blood
. 2024 Jul;
144(17):1765-1780.
PMID: 38991192
The genomics era has facilitated the discovery of new genes that predispose individuals to bone marrow failure (BMF) and hematological malignancy (HM). We report the discovery of ETS-related gene (ERG),...
2.
Brown F, Carmichael C
Methods Mol Biol
. 2024 Apr;
2806:31-40.
PMID: 38676794
Patient-derived xenograft (PDX) modeling is a valuable tool for the study of leukemia pathogenesis, progression, and therapy response. Engraftment of human leukemia cells occurs following injection into the tail vein...
3.
Radhakrishnan K, Truong L, Carmichael C
Front Immunol
. 2023 Aug;
14:1207360.
PMID: 37600794
The epithelial to mesenchymal transition (EMT) is a fundamental developmental process essential for normal embryonic development. It is also important during various pathogenic processes including fibrosis, wound healing and epithelial...
4.
Carmichael C, Wang J, Nguyen T, Kolawole O, Benyoucef A, De Maziere C, et al.
Blood
. 2020 May;
136(8):957-973.
PMID: 32369597
Modulators of epithelial-to-mesenchymal transition (EMT) have recently emerged as novel players in the field of leukemia biology. The mechanisms by which EMT modulators contribute to leukemia pathogenesis, however, remain to...
5.
Fagnan A, Bagger F, Pique-Borras M, Ignacimouttou C, Caulier A, Lopez C, et al.
Blood
. 2020 May;
136(6):698-714.
PMID: 32350520
Acute erythroleukemia (AEL or acute myeloid leukemia [AML]-M6) is a rare but aggressive hematologic malignancy. Previous studies showed that AEL leukemic cells often carry complex karyotypes and mutations in known...
6.
Brown A, Arts P, Carmichael C, Babic M, Dobbins J, Chong C, et al.
Blood Adv
. 2020 Mar;
4(6):1131-1144.
PMID: 32208489
First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes...
7.
Iacobucci I, Wen J, Meggendorfer M, Choi J, Shi L, Pounds S, et al.
Nat Genet
. 2019 Mar;
51(4):694-704.
PMID: 30926971
Acute erythroid leukemia (AEL) is a high-risk leukemia of poorly understood genetic basis, with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid leukemia. We compared genomic features of...
8.
Thirant C, Ignacimouttou C, Lopez C, Diop M, Le Mouel L, Thiollier C, et al.
Cancer Cell
. 2017 Mar;
31(3):452-465.
PMID: 28292442
Chimeric transcription factors are a hallmark of human leukemia, but the molecular mechanisms by which they block differentiation and promote aberrant self-renewal remain unclear. Here, we demonstrate that the ETO2-GLIS2...
9.
Carmichael C, Haigh J
Cells Tissues Organs
. 2017 Feb;
203(2):82-98.
PMID: 28214876
Snail family proteins are key inducers of the epithelial-mesenchymal transition (EMT), a critical process required for normal embryonic development. They have also been strongly implicated in regulating the EMT-like processes...
10.
Tang J, Carmichael C, Shi W, Metcalf D, Ng A, Hyland C, et al.
Proc Natl Acad Sci U S A
. 2013 Mar;
110(15):6091-6.
PMID: 23533276
To define genetic lesions driving leukemia, we targeted cre-dependent Sleeping Beauty (SB) transposon mutagenesis to the blood-forming system using a hematopoietic-selective vav 1 oncogene (vav1) promoter. Leukemias of diverse lineages...